Clinical Trial Update: Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluates a quadruplet regimen of ixazomib, lenalidomide, dexamethasone, and daratumumab in newly diagnosed multiple myeloma, with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)
• Decadron (Dexamethasone)
• NINLARO (ixazomib)
• Revlimid (lenalidomide)

Snippet

Sponsor: Mayo Clinic | Conditions: Plasma Cell Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2025-06-04